Phytomedicines in the Treatment of Migraine
Autor: | William Jeptha Davenport, Thilinie Rajapakse |
---|---|
Rok vydání: | 2019 |
Předmět: |
Migraine Disorders
Tanacetum parthenium law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy law Humans Medicine Pharmacology (medical) Migraine treatment Cannabis Plants Medicinal Traditional medicine business.industry Hypericum perforatum Petasites medicine.disease 030227 psychiatry Clinical trial Psychiatry and Mental health Migraine Plant Preparations Neurology (clinical) Psychopharmacology business Phytotherapy Hypericum 030217 neurology & neurosurgery |
Zdroj: | CNS Drugs. 33:399-415 |
ISSN: | 1179-1934 1172-7047 |
DOI: | 10.1007/s40263-018-0597-2 |
Popis: | Migraine is a disabling neurovascular disorder with few targeted, tolerable and effective treatments. Phytomedicines, or plant-based medicinal formulations, hold great promise in the identification of novel therapeutic targets in migraine. Many patients also turn toward herbal and plant-based therapies for the treatment of their migraines as clinical and preclinical evidence of efficacy increases. Patients seek effective and tolerable treatments instead of or in addition to current conventional pharmacologic therapies. We review some phytomedicines potentially useful for migraine treatment-feverfew (Tanacetum parthenium), butterbur (Petasites hybridus), marijuana (Cannabis spp.), Saint John's Wort (Hypericum perforatum) and the Damask rose (Rosa × damascena)-with respect to their mechanisms of action and evidence for treatment of migraine. The evidence for feverfew is mixed; butterbur is effective with potential risks of hepatotoxicity related to preparation; marijuana has not been shown to be effective in migraine treatment, and data are scant; Saint John's Wort shows relevant physiological activity but is a hepatic enzyme inducer and lacks clinical studies for this purpose; the Damask rose when used in topical preparations did not show efficacy in one clinical trial. Other plant preparations have been considered for migraine treatment but most without blinded randomized, placebo-controlled trial evidence. |
Databáze: | OpenAIRE |
Externí odkaz: |